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ABSTRACT
Rationale Detailed data on the characteristics and 
outcomes of patients with COVID-19 in sub- Saharan Africa 
are limited.
Objective We determined the clinical characteristics and 
treatment outcomes of patients diagnosed with COVID-19 
in Uganda.
Measurements As of the 16 May 2020, a total of 203 
cases had been confirmed. We report on the first 56 
patients; 29 received hydroxychloroquine (HCQ) and 27 
did not. Endpoints included admission to intensive care, 
mechanical ventilation or death during hospitalisation.
Main results The median age was 34.2 years; 67.9% 
were male; and 14.6% were <18 years. Up 57.1% of 
the patients were asymptomatic. The most common 
symptoms were fever (21.4%), cough (19.6%), rhinorrhea 
(16.1%), headache (12.5%), muscle ache (7.1%) and 
fatigue (7.1%). Rates of comorbidities were 10.7% 
(pre- existing hypertension), 10.7% (diabetes) and 7.1% 
(HIV), Body Mass Index (BMI) of ≥30 36.6%. 37.0% had 
a blood pressure (BP) of >130/90 mm Hg, and 27.8% 
had BP of >140/90 mm Hg. Laboratory derangements 
were leucopenia (10.6%), lymphopenia (11.1%) and 
thrombocytopenia (26.3%). Abnormal chest X- ray was 
observed in 14.3%. No patients reached the primary 
endpoint. Time to clinical recovery was shorter among 
patients who received HCQ, but this difference did not 
reach statistical significance.
Conclusion Most of the patients with COVID-19 presented 
with mild disease and exhibited a clinical trajectory not 
similar to other countries. Outcomes did not differ by HCQ 
treatment status in line with other concluded studies on 
the benefit of using HCQ in the treatment of COVID-19.
INTRODUCTION
COVID-19, a disease caused by the 
SARS- CoV-2 virus, was first reported in early 
December 2019 in Wuhan China.1 The 
number of patients confirmed to have the 
disease rapidly increased and on 30 January 
2020, and the disease was declared a public 
health emergency of international concern 
by the WHO. As of 16 May 2020, a total of 
4 396 392 confirmed cases and 300 441 deaths 
(6.8%) had been reported globally.2 In Africa, 
75 498 cases and 2561 (3.4%) deaths had 
been reported by 16 May 2020.3 Africa faces 
many well- documented barriers to addressing 
pandemics, and COVID-19 has the potential 
to strain existing health infrastructure.
The initial presentation of COVID-19 was 
of an acute respiratory illness, with many 
cases being diagnosed with pneumonia which 
rapidly progressed into respiratory failure.4 
Symptoms encountered among confirmed 
patients include cough, fever, myalgia, fatigue, 
abdominal pain, diarrhoea, nausea, vomiting, 
headache and dyspnoea.4 It is now estab-
lished that the majority of persons infected 
with SARS- CoV-2 virus are asymptomatic. A 
study of 215 pregnant mothers universally 
tested in New York found that 84.6% were 
negative, 13.5% positive and asymptomatic 
and only 1.9% were positive and symptom-
atic.5 Patients with COVID-19 are character-
ised by the presence of comorbidities with 
Key messages
 ► Whereas COVID-19 is associated with high mortal-
ity, with a global mortality rate of 6.8%, with about 
13.8% of patients developing severe disease and 6% 
developing critical illness, the disease has not been 
well characterised in sub- saharan African countries.
 ► Most of the initial patients with COVID-19 in Uganda 
presented with mild disease and exhibit a clinical 
trajectory not similar to other countries.
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diabetes, hypertension, asthma, chronic obstructive 
pulmonary disease (COPD), chronic kidney disease and 
a range of heart diseases being among the most encoun-
tered comorbidities.4 6 7 Several laboratory and imaging 
derangements, such as leucopenia, thrombocytopenia, 
raised d- dimers, C reactive protein (CRP) and high cyto-
kine levels, have been reported among patients with 
COVID-19.4 By presentation, majority of patients have 
radiological changes on chest radiograph; commonly 
bilateral infiltrates and ground- glass opacities (GGO) are 
seen on chest CT scan images.4 6 7
COVID-19 is a fatal disease, and globally the mortality 
rate is 6.8%.2 It is estimated that about 13.8% of patients 
with COVID-19 develop severe disease, and 6% develop 
critical illness defined as respiratory failure, shock and 
multiple organ dysfunction or failure, and dyspnoea, 
respiratory rate of ≥30 breaths/min, oxygen saturation of 
≤93%, and partial pressure of arterial oxygen to fraction 
of inspired oxygen ratio 50% within 24–48 hours, respec-
tively.8 9
Currently, there are no proven treatments and vaccines 
for COVID-19. Several repurposed and new drugs have 
been reported in compassionate use and small trials to 
offer some benefit.9 These drugs include the antimalar-
ials (chloroquine and hydroxyl chloroquine), antivirals 
such as remdesivir and favipiravir, and antiretroviral 
combination therapies such as lopinavir/ritonavir.9–13 
Anti- inflammatory drugs such as tocilizumab have been 
reported to have some effects.14 Convalescent plasma 
and ivermectin have additionally been trialled.11 15 Glob-
ally, publications on the characteristics, outcomes and 
efficacy of candidate medications for COVID-19 are 
emerging, helping clinicians, public health scientists 
and political leaders frame appropriate epidemic control 
responses. In Uganda and most of Africa, COVID-19 liter-
ature is limited. This is probably because the disease has 
recently arrived in Africa but could also be due to limited 
capacity to simultaneously respond to the epidemic while 
collecting research publishable data at the same time. 
Uganda reported the first case of COVID-19 on 21 March 
2020. Two treatment centres were established at Mulago 
National Specialised Hospital and Entebbe Regional 
Referral Hospital. We quickly formed a research group 
called COVIDRES- Uganda. The group is a multidis-
ciplinary research group consisting of clinical, public 
health, behavioural and biomedical scientists. This group 
allowed the conduct of research alongside clinical care. 
The purpose of this paper was to describe the character-
istics and treatment outcomes of the first patients with 
COVID-19 admitted at the two hospitals. We further 
compare the treatment outcomes by hospitals since one 
hospital provided hydroxychloroquine (HCQ) and the 
other did not.
METHODS
Design, participants and study sites
This study is a prospective cohort study. Patients diag-
nosed with confirmed COVID-19 in Uganda are all 
eligible to participate. The only exclusion criterion is 
failure to provide written informed consent/assent. 
Patients were consecutively enrolled and followed up 
until the first occurrence of one of the outcomes of 
discharge, transfer to intensive care unit (ICU), mechan-
ical ventilation or death. In this paper, we describe only 
patients hospitalised at Mulago National Specialised 
Hospital and Entebbe Regional Referral Hospital, the 
largest COVID-19 treatment facilities in the country. 
Mulago National Specialised Hospital is a tertiary health 
facility with about 900 admission beds and 36 adult ICU 
beds located in the capital city of Uganda, Kampala. At 
the time of the outbreak, the hospital was undergoing 
a major renovation. However, one block, block A, had 
been completed. The entire block was made ready and 
converted into a COVID-19 screening (levels 2 and 3) 
and treatment centre (levels 4, 5 and 6). At the time of 
this article, only level 4 was being used as a treatment 
centre due to the limited number of patients. Entebbe 
Regional Referral Hospital is located in Entebbe city at 
the shores of Lake Victoria. Entebbe city is home to the 
only international airport in Uganda, the Entebbe Inter-




At the time the first cases of COVID-19 were diagnosed in 
the country, there was no standardised case management 
protocol for the country. Sites managed patients based 
on individual specialists’ advice and basing on interna-
tional management guidelines, notably those published 
by WHO.16 For this reason, the management of patients 
differed in many ways at the two hospitals. At Mulago 
National Specialised Hospital, patients were managed in 
an open spaceward of 55 beds in total separated in cubi-
cles of 4 beds each. The ward has four private rooms, three 
of which were occupied by patients. Adjacent to the ward, 
there was an office space that was used by health workers 
for donning personal protection equipment (PPE) and 
storing supplies. At Entebbe Regional Referral Hospital, 
similar open space wards were used. Health worker 
teams were multidisciplinary, consisting of specialist 
internal medicine physicians, a paediatrician, general 
practitioners, nurses, pharmacists, radiologists, patholo-
gists, microbiologists, psychologists and psychiatrists. At 
Entebbe Regional Referral Hospital, similar composition 
of the team was used, but the team was smaller as some 
specialists are not part of the staffing norm of a regional 
referral hospital. PPE was used all the time and consisted 
of N95 masks, coveralls, aprons, gaggles, gumboots and 
gloves. Wards were periodically sanitised and hand sani-
tisers were used between patients. Patients were reviewed 
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by specialist physicians once a day and by nurses and 
general physicians three times a day, that is, day shift, 
evening shift and night shift. At each review, saturation 
of peripheral oxygen (SpO2), pulse rate (PR), tempera-
ture, blood pressure (BP) and symptoms were charted. 
Other clinical assessments were performed as clinically 
relevant. Patients were discharged if they were asympto-
matic, had completed 14 days of hospitalisation and had 
two negative reverse transcriptase PCR (RT- PCR) tests at 
least 24 hours apart.
Laboratory and radiological examinations
We performed baseline chest X- ray (CXR), ECG and labo-
ratory tests. Baseline laboratory tests included complete 
blood count, liver and kidney function tests, CRP, d- di-
mers and high- sensitivity troponin. In addition to the 
clinical laboratory tests, consenting patients had the 
following samples obtained for biobanking: saliva, stool, 
blood, and nasal and oropharyngeal swabs. Swabs and 
blood sampling were repeated weekly until discharge. 
Clinical laboratory tests were repeated if indicated. One 
patient underwent CT scanning; one had blood culture; 
and patients with diabetes had blood sugar monitoring 
and glyacaeted haemoglobin (HbA1c) testing. At 
Entebbe Regional Referral Hospital, some laboratory 
tests were not performed and CXR was not done due to 
logistical constraints.
Medications
Medications administered differed between sites. At 
the Entebbe Regional Referral Hospital site, HCQ was 
administered for patients who were symptomatic, while at 
the Mulago National Specialised Hospital site it was not 
administered. Patients who had respiratory symptoms 
had a combination of ampiclox (a generic ampicillin/
cloxacillin combination) or augmentin plus azithro-
mycin. Those with radiological evidence of lung involve-
ment had the option of receiving intravenous ceftriazone 
plus azithromycin. All patients received vitamin C tabs 
supplementation. Comorbidities were treated as indi-
cated.
Definitions
Fever was defined as a temporal temperature of 37.5°C 
or higher, leucopenia as total white cell count of ≤4000/
mL3 and lymphocytopenia as a lymphocyte count of less 
than 1500 cells/mm3. Thrombocytopenia was defined 
as a platelet count of less than 150 000/mm3. Anaemia 
as haemoglobin level of ≤10 g/dL, high aspartate 
aminotransferase (AST) as AST>40 U/L, high alanine 
aminotransferase (ALT) as ALT>40 U/L, high creatinine 
as creatinine≥133 μmol/L, high lactate dehydrogenase 
(LDH) as LDH ≥250 U/L, high troponin as troponin 
≥0.06 ng/mL, high total bilirubin as total bilirubin>17.1, 
high CRP as CRP≥10 mg/L and high d- dimers as d- dimer 
levels of ≥0.5 mg/L. Asymptomatic COVID-19 was defined 
as the absence of cough, fever (reported), temperature 
of ≥37.5°C, rhinorrhea, fatigue and shortness of breath.
Statistical analysis
We used descriptive statistics including proportions, 
means, and medians to describe the patients’ character-
istics stratified by the two study sites; Mulago National 
Specialised Hospital and Entebbe Regional Referral 
Hospital. Chi- square or Fisher’s exact tests were used 
to compare proportions, t- test to compare means, and 
Wilcoxon rank- sum test to compare medians between 
study sites. We used graphical aids to visualise trend in 
various symptoms and vital signs observed over a period 
of 14 days stratified by study sites. Survival analysis using 
Kaplan- Meier curves was used to estimate recovery rates 
from major symptoms of COVID-19 observed over the 
first 14 days. Log- rank test was used to compare recovery 
rates between sites. We also analysed for factors associ-
ated with asymptomatic infection of COVID-19 and we 
used OR with 95% CIs to quantify the associations. All 
analyses were done using STATA V.15.
Patient and public involvement statement
Given the strict national lockdown measures put in place 
due to the COVID-19 pandemic, we did not involve 
patients in the design of the study. Instead, through the 
Ministry of Health COVID-19 task Force, the public was 
informed about the recruitment and conduct of the 
study. Through the Ministry of Health public broadcasts 
and presidential COVID-19 updates, the general public 
has been informed about the study findings.
RESULTS
Sociodemographic characteristics
The baseline characteristics of the first 56 patients 
treated at Mulago National Specialised Hospital and 
Entebbe Regional Referral Hospital are presented in 
table 1. Of the 56 patients, 25 were treated at Mulago 
National Specialised Hospital and 31 were treated at 
Entebbe Regional Referral Hospital. The mean age of 
all the patients was 34.2 years with an SD of 15.5 years; 
Mulago National Specialised Hospital versus Entebbe 
Regional Referral Hospital (42.2 vs 27, p=0.0003). The 
youngest patient was 9 months while the oldest was 66 
years. A total of 8 (14.6%) patients were under the age 
of 18 years. By gender, 67.9% of the patients were male. 
Only one patient reported a history of tobacco smoking.
Symptoms and comorbidities
Patients who had any of the major COVID-19 symptoms 
defined as the presence of fever (reported), temperature 
of ≥37.5°C, cough, shortness of breath, fatigue or rhinor-
rhea constituted 42.9% (24 patients). The most common 
symptoms were fever (21.4%), cough (19.6%), rhinor-
rhea (16.1%), headache (12.5%), muscle ache (7.1%) 
and fatigue (7.1%). No patient reported shortness of 
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Referral Hospital P value
Enrolment hospital, N 56 25 31
  Age (years) n=55 n=25 n=30
   Mean (SD) 34.2 (15.5) 42.2 (15.2) 27.6 (12.5) 0.0003*
   Median (IQR) 33 (25–43) 42 (33–54) 27 (22–35) 0.0004†
   Categorical, n (%)
    7–17 8 (14.6) 2 (8.0) 6 (20.0) 0.001‡
    18–29 13 (23.6) 2 (8.0) 11 (36.7)
    30–39 17 (30.9) 7 (28.0) 10 (33.3)
    40–66 17 (30.9) 14 (56.0) 3 (10.0)
Sex, n (%) n=56 n=25 n=31
  Male 38 (67.9) 17 (68.0) 21 (67.7) >0.999§
  Female 18 (32.1) 8 (32.0) 10 (32.3)
Occupation, n (%) n=46 n=25 n=21
  Unemployed 1 (2.2) 1 (4.0) 0 (0.0) 0.012‡
  Housewife 4 (8.7) 3 (12.0) 1 (4.8)
  Peasant farmer 2 (4.4) 0 (0.0) 2 (9.5)
  Business 17 (37.0) 9 (36.0) 8 (38.1)
  Armed forces 2 (4.4) 2 (8.0) 0 (0.0)
  Services and sales 4 (8.7) 4 (16.0) 0 (0.0)
  Professionals 2 (4.4) 2 (8.0) 0 (0.0)
  Technicians 1 (2.2) 1 (4.0) 0 (0.0)
  Other 13 (28.3) 3 (12.0) 10 (47.6)
Smoking status, n (%) n=56 n=25 n=31
  Never/unknown 55 (98.2) 25 (100) 30 (96.8) >0.999‡
  Former/current 1 (1.8) 0 (0.0) 1 (3.2)
Symptoms, n (%) n=56 n=25 n=31
  Any (fever, cough, shortness of 
breath, rhinorrhea, fatigue)
24 (42.9) 11 (44.0) 13 (41.9) 0.877§
  Fever 12 (21.4) 4 (16.0) 8 (26.8) 0.516‡
  Cough 11 (19.6) 8 (32.0) 3 (9.7) 0.048‡
  Shortness of breath 0 (0.0) 0 (0.0) 0 (0.0) ¶
  Muscle ache 4 (7.1) 4 (16.0) 0 (0.0) 0.034‡
  Confusion 0 (0.0) 0 (0.0) 0 (0.0) ¶
  Headache 7 (12.5) 3 (12.0) 4 (12.9) >0.999‡
  Sore throat 3 (5.4) 1 (4.0) 2 (6.5) >0.999‡
  Rhinorrhea 9 (16.1) 6 (24.0) 3 (9.7) 0.272‡
  Chest pain 2 (3.6) 0 (0.0) 2 (6.5) 0.497‡
  Diarrhoea 2 (3.6) 1 (4.0) 1 (3.2) >0.999‡
  Nausea and vomiting 2 (3.6) 1 (4.0) 1 (3.2) >0.999‡
  Cough with sputum production 3 (5.4) 2 (8.0) 1 (3.2) 0.581‡
  Cough with haemoptysis 0 (0.0) 0 (0.0) 0 (0.0) ¶
  Wheezing 0 (0.0) 0 (0.0) 0 (0.0) ¶
  Joint pain 2 (3.6) 2 (8.0) 0 (0.0) 0.195‡
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Referral Hospital P value
  Inability to walk 0 (0.0) 0 (0.0) 0 (0.0) ¶
  Lower chest pain 0 (0.0) 0 (0.0) 0 (0.0) ¶
  Seizures 0 (0.0) 0 (0.0) 0 (0.0) ¶
  Abdominal pain 3 (5.4) 1 (4.0) 2 (6.5) >0.999‡
  Conjunctivitis 1 (1.8) 1 (4.0) 0 (0.0) 0.446‡
  Skin rash 1 (1.8) 1 (4.0) 0 (0.0) 0.446‡
  Skin ulcers 0 (0.0) 0 (0.0) 0 (0.0) ¶
  Lymphadenopathy 0 (0.0) 0 (0.0) 0 (0.0) ¶
  Bleeding 0 (0.0) 0 (0.0) 0 (0.0) ¶
  General weakness 0 (0.0) 0 (0.0) 0 (0.0) ¶
  Inability to feed 0 (0.0) 0 (0.0) 0 (0.0) ¶
  Reduced activity 0 (0.0) 0 (0.0) 0 (0.0) ¶
  Pain on swallowing 0 (0.0) 0 (0.0) 0 (0.0) ¶
  Others 0 (0.0) 0 (0.0) 0 (0.0) ¶
Vital signs
  Temperature (°C) n=56 n=25 n=31
   Mean (SD) 36.5 (0.81) 36.5 (0.94) 36.5 (0.71) 0.763*
   Median (IQR) 36.4 (36.2–36.6) 36.5 (36.3–36.8) 36.4 (36.2–36.5) 0.252†
   Categorical
    <37.5 51 (91.1) 23 (92.0) 28 (90.3) >0.999‡
    37.5–38.0 2 (3.6) 1 (4.0) 1 (3.2)
    38.1–39.0 3 (5.4) 1 (4.0) 2 (6.5)
    >39.0 0 (0.0) 0 (0.0) 0 (0.0)
  SPO2 n=51 n=20 n=31
   Mean (SD) 97.8 (1.2) 97.9 (1.4) 97.7 (1.1) 0.755*
   Median (IQR) 98 (97–99) 98 (97–99) 98 (97–99) 0.697†
   <93, n (%) 0 (0.0) 0 (0.0) 0 (0.0) ¶
  Pulse rate n=54 n=24 n=29
   Mean (SD) 86.9 (13.0) 86.8 (14.3) 87.0 (12.0) 0.956*
   Median (IQR) 87 (78–95) 86 (78–91) 88 (78–96) 0.690†
  Blood pressure (mm Hg), n (%) n=54 n=24 n=30
   >130/90 20 (37.0) 13 (54.2) 7 (23.3) 0.020§
   >140/90 15 (27.8) 9 (37.5) 6 (20.0) 0.154§
  Body Mass Index n=19 n=19 n=0
   Mean (SD) 28.3 (6.2) 28.3 (6.2) ¶
   Median (IQR) 27.2 (23.1–32.0) 27.2 (23.1–32.0) ¶
   <18.5 0 (0.0) 0 (0.0) ¶
   18.5–24.9 7 (36.8) 7 (36.8)
   25–29.9 5 (26.3) 5 (26.3)
   30+ 7 (36.8) 7 (36.8)
*t- Test.
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breath. A comparison of sociodemographic, clinical and 
laboratory parameters assessed in the study did not find 
statistical differences between asymptomatic and sympto-
matic patients (online supplemental table 1).
Up to 26.8% of the patients reported at least one 
comorbidity (any of tuberculosis, HIV, hypertension, 
diabetes, asthma, COPD, cancer, chronic kidney disease, 
chronic liver disease and chronic neurological disor-
ders). The most common comorbidities were hyperten-
sion (10.7%), diabetes (10.7%), cardiovascular disease 
other than hypertension (8.9%) and HIV (7.1%). We 
obtained Body Mass Index (BMI) from 19 patients. The 
median BMI was 27.2 (IQR 23.1–32.0). Seven of these 
patients (36.6%) had a BMI of more than 30, 5 (26.3%) 
had BMI 25.0–29.9, 7 (36.8%), 18.5–24.9, and no patient 
had a BMI of less than 18.5.
Vital signs
Five patients (8.9%) had a temperature of ≥37.5°C; 
20 patients (37.0%) had a BP of >130/90 mm Hg at 
baseline; Mulago National Specialised Hospital versus 
Entebbe Regional Referral Hospital (54.2% vs 23.3%, 
p=0.020) while 15 patients (27.8%) were found to have 
BP >140/90 mmHg. Data on daily symptoms and vital 
signs (BP, temperature, PR and SpO2) were available for 
the first for 51 patients. The trajectory of these symptoms 
and signs over the 14 days is illustrated in figure 1. Most 
of the symptoms had resolved by day 10, although the 
cough persisted until day 12. At the Mulago National 
Specialised Hospital site, there was a peak in symptoms 
at around day 4 and another one around day 8. At the 
Entebbe Regional Referral Hospital site, the trajectory of 
symptoms had four identifiable peaks: around day 2, 5, 8 
and 12. Many patients had high BPs at baseline (note only 
6 (10.7%) without a prior diagnosis of hypertension). 
High BPs continued throughout the 14 days; higher 
at the Mulago National Specialised Hospital site than 
Entebbe Regional Referral Hospital site (figure 1C,D).
Laboratory, electrocardiograph and imaging findings
Logistical constraints precluded performance of some key 
COVID-19 care laboratory tests. The results of tests that 
were performed are shown in table 2. Five patients (10.6%) 
had leucopenia (total white cell count≤4000/mL)3; four 
of these five were from the Mulago National Specialised 
Hospital site. Other laboratory abnormalities were as 
follows: lymphopenia 11.1%, thrombocytopenia 26.3%, 
AST>40 U/L 8.5%, ALT>40 U/L 12.8% and total bilirubin 
>17.1 μmol/L 13.3%. Electrocardiograph was performed 
on 32 patients. All electrocardiograph results were normal 
Figure 1 Percentage distribution of symptoms (top row) and vital statistics (bottom row) observed among patients with 
COVID-19 over 14 days stratified by sites: Mulago (A,C) and Entebbe (B,D). BP, blood pressure; PR, pulse rate ; SpO2, 
saturation of peripheral oxygen.
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with the exception of bradycardia and first- degree heart 
block in a 66- year patient who was being treated for hyper-
tension with atenolol before admission. We performed 
CXRs on 21 patients, three of which had abnormal 
results consisting of bilateral infiltrates (two patients) and 
unilateral right lower zone infiltrates (one patient). We 
performed a CT scan on one patient to further evaluate 
reasons for persistent clinical and radiological features 
noted from the preliminary investigations.
Treatments and clinical outcomes
Data on treatments provided to the patients are 
presented in table 3. Patients at the Entebbe Regional 






Referral Hospital/+HCQ P value
Laboratory   
  White cell count/mm3 n=47 n=21 n=26   
  Median (IQR) 5.1 (4.2−6.2) 5.0 (4.2−6.3) 5.1 (4.5−6.1) 0.473*
  Distribution, n (%)   
  ≥10 000/mm3 0 (0.0) 0 (0.0) 0 (0.0)   
  4001−<10 000/mm3 42 (89.4) 17 (81.0) 25 (92.1) 0.158†
  ≤4000/mm3 5 (10.6) 4 (19.0) 1 (3.9)   
Neutrophil count n=45 n=19 n=26   
  Median (IQR)/mm3 2 (2−2) 2 (1−2) 2 (2−2) 0.092*
  Distribution, n (%)   
  ≤1500/mm3 7 (15.6) 5 (26.3) 2 (7.7) 0.114†
Lymphocyte count n=45 n=19 n=26   
  Median (IQR)/mm3 2.3 (1.8−2.9) 2.4 (1.4−2.9) 2.3 (2.0−2.9) 0.340*
  Distribution, n (%)   
  ≤1500/mm3 5 (11.1) 5 (26.3) 0 (0.0) 0.010†
Platelets per mm3 n=19 n=18 n=1   
  Median (IQR) 227 (121−275) 224.5 (121−275) 232 0.855*
  Distribution, n (%)   
   <150 000/mm3 5 (26.3) 5 (27.8) 0 (0.0) >0.999†
Haemoglobin (g/L) n=19 n=18 n=1   
  Median (IQR) 1.47 (1.34−1.60) 1.47 (1.34−1.57) 1.62 0.273*
  Distribution, n (%)   
  ≤1.0 g/L 2 (10.5) 2 (11.1) 0 (0.0) >0.999†
  Aspartate aminotransferase >40 U/L, n/N (%) 4/47 (8.5) 3/18 (16.7) 1/29 (3.5) 0.150†
  Alanine aminotransferase >40 U/L, n/N (%) 6/47 (12.8) 5/18 (27.8) 1/29 (3.5) 0.025†
  LDH≥250 U/L, n/N (%) lactate 0/11 (0.0) 0/11 (0.0)   
  Creatinine ≥133 μmol/L, n/N (%) 0/48 (0.0) 0/19 (0.0) 0/29 (0.0) –
  Troponin, median (IQR) 0.1 (0.1–0.1) 0.1 (0.1–0.1) 0.1 (0.1–0.1) 0.532*
  Total bilirubin >17.1 μmol/L, n/N (%) 2/15 (13.3) 2/14 (14.3) 0/1 (0.0) >0.999†
  Total bilirubin, median (IQR) 2.5 (0–12.9) 2.4 (0–11.7) 13.8 0.232*
  C reactive protein ≥10 mg/L, n/N (%) 6/49 (12.2) 5/24 (20.8) 1/25 (4.0) 0.098†
  Median (IQR) 1.7 (0.5–8.1) 4.0 (1.8–9.7) 0.5 (0.5–1.4) <0.001*
Procalcitonin ng/mL n=49 n=24 n=25   
  Median (IQR) 0.1 (0.1–0.12) 0.1 (0.1–0.12) 0.1 (0.1–0.13) 0.614*
Lactate dehydrogenase n=49 n=24 n=25   
  Median (IQR) 330 (287–402) 318 (244–385) 330.5 (295.5–402.5) 0.282†
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Referral Hospital site received HCQ (29), while all the 
24 patients at the Mulago National Specialised Hospital 
site did not receive HCQ. Patients were treated with a 
range of antibiotics including azithromycin, ampicillin/
cloxacillin combination and Augmentin. The average 
antibiotic prescription rate was 76.4%. The primary 
outcomes (admission to ICU, mechanical ventilation or 
death) did not occur in any patient. The average length 
of hospitalisation was 20.6 days. The time to clinical 
recovery (TTCR), defined as the time to clearance of the 
major COVID-19 symptoms, is shown in figure 2. TTCR 
was earlier among patients treated with HCQ (6.4 days) 
and those who did not (8.6 days), but this difference did 
not reach statistical significance (p=0.204, figure 2A) 
We monitored the patients for known HCQ side effects 
among those treated with or without HCQ. The rates of 
these events are presented in online supplemental table 
2. Although the number of patients is small, the rates 
of these events did not seem to be significantly higher 
among HCQ- treated patients.
Table 3 Treatments and clinical outcomes of patients infected with SARS- CoV-2 during the first 2 weeks of admission at 





Referral Hospital P value
Treatments n=55 n=24 n=31
  Hydroxychloroquine, n (%) 29 (52.7) 0 (0.0) 29 (93.6) <0.001*
  Antibiotics, n (%) 42 (76.4) 12 (50.0) 30 (96.8) <0.001*
Clinical outcomes at data cut- off, no (%)
  Length of hospitalisation (days) n=47 n=20 n=27
   Mean (SD) 20.6 (4.1) 19.3 (1.5) 21.5 (5.1) 0.068†
   Median (IQR) 20 (19–21) 19 (18–20) 21 (19–22) 0.012‡
  Discharged from hospital with two negative RT- 
PCRs
56 25 31
  Death 0 0 0
  Admitted to intensive care unit 0 0 0
*Fisher’s exact test.
†t- Test.
‡Wilcoxon rank- sum test.
RT- PCR, reverse transcriptase PCR.
Figure 2 KM curves showing proportion of symptomatic patients with COVID-19 19 recovering from various symptoms; any 
major symptom (top left), fever (top right), cough (bottom left) and sore throat (bottom right) over 14 days of follow- up. Major 
symptoms include fever, cough, sore throat, rhinorrhea and shortness of breath. KM, Kaplan- Meier.
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DISCUSSION
In this prospective study, we describe the characteris-
tics and outcomes of 56 treated patients with COVID-19 
at two hospitals in Uganda. The median age of these 
patients was 33 years, and 67.9% of the patients were 
male. The predominance of male gender among patients 
with COVID-19 is similar to what has been reported 
elsewhere.7 17 Like most respiratory diseases COVID-19 
predominance in men may reflect exposure dynamics 
since men are usually more outdoor and more likely to 
be exposed than women. The mean age we observed is, 
however, different from reports in China, Europe and 
the USA.17 In China, Guan et al7 reported a mean age of 
47 years, while in the USA, Richardson et al18 reported 
a mean age of 63 years. The young age of the Ugandan 
patients with COVID-19 is probably a reflection of the 
general population structure where our population is 
composed mainly of young people.19 Another reason 
could be the source of the initial patients with COVID-19 
in Uganda, which was mainly composed of youthful 
travellers returning from their workplaces abroad. We 
also note that the 56 patients include eight children 
belonging to a choir who were returning from abroad. 
This could also have skewed the cohort’s age downwards.
We found that up to 56.1% of the patients were asymp-
tomatic and not in keeping with most studies on hospi-
talised patients. In most studies, over 80% of the patients 
have one or more COVID-19 symptoms by the time of 
hospitalisation.4 7 17 Our results are, however, in line 
with findings from a study by Arons et al20 and Sutton et 
al.5 In the study by Arons et al20 among 89 residents of 
a skilled nursing home, 56% of persons found positive 
were asymptomatic.20 The testing in this study was part of 
a survey. In the case of Uganda, most of the persons were 
tested as part of routine surveillance because they either 
had travelled or had been in contact with a confirmed 
case. It seems therefore that the absence of symptoms 
could be due to early detection. In the study by Arons et 
al20 referred to earlier, they reassessed the asymptomatic 
persons again. They found that 24 of the 27 asymptom-
atic patients subsequently developed symptoms (median 
time to onset of 4 days). This was not the case among our 
patients, suggesting that there could be other reasons for 
lack of symptoms in our cohort.20 Asymptomatic disease 
has gained attention following the finding that disease 
transmission occurs even in the absence of symptoms.21 
If indeed most patients with COVID-19 in Uganda and 
Africa will be asymptomatic, control efforts need to be 
geared towards mass testing as many of those infected will 
not be sick and will therefore not be presenting at health 
facilities for testing and treatment.
Comorbidity has been a common finding in patients 
with COVID-19 and has been found to be associated with 
worse outcomes.4 7 17 22 In this study, we found that up 
to 26.8% of the patients reported at least one comor-
bidity (any of tuberculosis, HIV, hypertension, diabetes, 
asthma, COPD, cancer, chronic kidney disease, chronic 
liver disease or chronic neurological disorders). The 
most common comorbidities were hypertension (10.7%), 
diabetes (10.7%), cardiovascular disease other than 
hypertension (8.9%) and HIV (7.1%). The rate of having 
any of the listed comorbidities and the individual comor-
bidity rates are much lower than reported elsewhere.7 17 
The lower rates are probably a reflection of lower rates 
of the same diseases in the general population but could 
also be due to lower rates of diagnosis of these diseases 
in the general population. A case in point is hyperten-
sion; only six patients reported a history of hypertension. 
However, as can be seen in table 1, 37% of the patients 
had BP>130/90 mm Hg, and 27.8% had BP higher than 
140/90 mm Hg. Living with undiagnosed hypertension 
has been reported in several studies in Uganda.23 A 
study by Kayima et al23 found that among 553 hyperten-
sive persons, only 13.7% were aware of their diagnosis. 
The underdiagnosis notwithstanding, 37% prevalence of 
hypertension in these patients is higher than that found 
in general population studies in Uganda.23–25 Anxiety 
due to the fear of the disease could explain this high 
baseline BP. Further research is needed to establish if 
there is a direct link between SARS- CoV-2 virus infection 
and high BP, especially through the hypothalamic–pitu-
itary–adrenal axis.
The rates of laboratory derangements investigated 
were lower than those reported in cohorts elsewhere, 
in keeping with the mild nature of the disease in the 
patients we studied.7 For example, we found leuco-
penia in 10.6% of the patients, but Guan et al7 found 
it at 33.7% among Chinese patients; lymphopenia was 
11.1% compared with 80.4% found in China. The same 
applied to CXR abnormalities where we found that only 
3 out of 21 patients who underwent this examination 
had abnormalities. In the Guan et al7 study, this rate was 
59.1%.
In this initial cohort of 56 patients, no death, admis-
sion to ICU or mechanical ventilation was observed. With 
the exception of two patients, almost all had mild disease 
at admission and none deteriorated to severe or critical 
disease, a clinical trajectory that has not been observed 
in other countries. This patient, a 40- year- old man, was 
admitted with RT- PCR- confirmed COVID-19. He had 
been previously diagnosed with hypertension treated 
with calcium channel blockers and a thiazide diuretic. 
He had a week- long cough and during his stay, low SpO2 
ranging between 92% and 95% was noted. His baseline 
CXR (2 April) showed bilateral infiltrates (figure 3A and 
follow- up CXRs (6 and 17 April, respectively; figure 3B,C). 
The 17 April CXR showed marked improvement. On 19 
April before discharge, we performed chest CT scans on 
this patient. The scan showed multiple peripheral and 
subpleural GGOs with associated interlobular septal 
thickening in all segments of the lung parenchyma. 
There was coalescing with a tendency to form air space 
consolidation. Selected slices from the chest CT scans 
are shown (figure 3). Although CXR had shown marked 
improvement, a CT scan performed later showed pres-
ence of pathology (figure 4).
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Death, admission to ICU and mechanical ventilation 
were observed at rates of 21% death, 14.2% admission to 
ICU and 3.2% mechanical ventilation in a study involving 
5700 Americans by Richardson et al.18 In China, the rates 
were 6.1% for death, 5% for admission to ICU and 2.3% 
for mechanical ventilation.7 The reasons for the lack of 
these adverse outcomes are not clear to us, but we think it 
could be due to the small sample size. It could also be due 
to the mild nature of the disease, with the reasons for the 
disease being mild not known at this point in time. The 
low rates of comorbid disease are probably a key factor 
since these have been consistently found to be associated 
with adverse outcomes.7 18 22 Several studies suggest that 
the viral load patients with COVID-19 exhibit is linked 
to the initial dose of the virus at the time of infection, 
and the viral load in turn determines the severity of the 
disease, although most of such studies are small and retro-
spective.26 27 Most of the Ugandan patients were detected 
among travellers whose exposures during travel could 
have been lower, hence low viral load at the beginning 
of infection and hence mild disease. Further research is 
needed if this similar trend continues to be observed.
Most of the patients in this cohort received supportive 
care and many received antibiotics. The main driving 
factor for the high antibiotic use is the entrenched 
practice of prescribing antibiotics for respiratory symp-
toms in our setting. In addition, there is evidence that 
secondary bacterial infection occurs following respira-
tory viral infection. When they occur, they are usually 
due to Streptococcus pneumonia, Haemophilus influenza, 
and Staphylococcus aureus.28 However, secondary bacte-
rial infection in COVID-19 has been reported to be 
rare.18 In view of this finding that secondary bacterial 
infections are uncommon in COVID-19 as opposed 
to other viral pneumonias, we do not recommend 
routine use of antibiotics in the treatment of COVID-
19. A comparison of 29 patients who received HCQ 
to 24 patients who did not received HCQ showed that 
there was no difference in terms of mortality, admission 
to ICU, mechanical ventilation and TTCR. TTCR was 
shorter for the HCQ group, but it did not reach statis-
tical significance. HCQ is prescribed in many centres 
around the world for the treatment of COVID-19. HCQ 
was reported to result in improved viral clearance in a 
small study done in France.12 A recently rapid review has 
identified 38 studies on the use of HCQ for treatment 
of COVID-19 (8 randomised clinical trials and 30 obser-
vational studies).29 This review notes the low method-
ological quality of the identified studies but concludes 
that the available evidence is sufficient to conclude that 
HCQ has no benefit in the treatment and prevention 
of COVID-19.29 Our findings, although from a small 
Figure 3 Posteroanterior chest X- ray images of a 40- year- 
old male hypertensive Ugandan admitted with reverse 
transcriptase PCR confirmed COVID-19 at baseline (A), 4 
days (B) and 15 days (C) postadmission at Mulago National 
Specialised Hospital.
Figure 4 CT scan images of the 40- year- old male Ugandan patient with COVID-19 at discharge (17 days postadmission).
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observation study, are in line with studies included in 
this review.
Our study has limitations, including the small sample 
size, and limitation of tests, including absence of viral 
clearance monitoring. The outcomes by HCQ are also 
limited by lack of randomisation to HCQ treatment.
In conclusion, most of the patients with COVID-19 
presented with mild disease and exhibited a clinical 
trajectory not similar to other countries. Outcomes did 
not differ by HCQ treatment status in line with other 
concluded studies on the use of HCQ in the treatment 
of COVID-19.
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